Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aquarius Surgical TechnologiesAQQRF Cyclically Adjusted PS Ratio is 0.42 as of Jul. 21, 2026, which is 83% below its 10-year median of 2.50. The stock has 4 warning signs investors should review. Among 521 Medical Devices & Instruments companies, Aquarius Surgical Technologies ranks better than 86.37% on this metric.
The historical rank and industry rank for Aquarius Surgical Technologies's Cyclically Adjusted PS Ratio or its related term are showing as below:
AQQRF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.17 Med: 2.5 Max: 17.4
Current: 0.41
During the past years, Aquarius Surgical Technologies's highest Cyclically Adjusted PS Ratio was 17.40. The lowest was 0.17. And the median was 2.50.
AQQRF's Cyclically Adjusted PS Ratio is ranked better than 86.37% of 521
companies
in the Medical Devices & Instruments industry
Industry Median: 2.28
vs AQQRF: 0.41
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Aquarius Surgical Technologies's adjusted revenue per share data for the three months ended in Dec. 2025 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.01 for the trailing ten years ended in Dec. 2025.
Shiller PE for Stocks: The True Measure of Stock Valuation
Aquarius Surgical Technologies (OTCPK:AQQRF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Aquarius Surgical Technologies Cyclically Adjusted PS Ratio Related Terms
Aquarius Surgical Technologies Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aquarius Surgical Technologies Cyclically Adjusted PS Ratio Chart
AQQRF vs ABT, SYK, MDT: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, Aquarius Surgical Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquarius Surgical Technologies Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aquarius Surgical Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Aquarius Surgical Technologies's Cyclically Adjusted PS Ratio falls into.
Aquarius Surgical Technologies Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.42 mean?
Aquarius Surgical Technologies (AQQRF) has a Cyclically Adjusted PS Ratio of 0.42 as of Jul. 21, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aquarius Surgical Technologies and its competitors. This is 83% below median its historical median of 2.50. Over the past decade, Aquarius Surgical Technologies' Cyclically Adjusted PS Ratio has ranged from 0.17 to 17.40. According to the industry distribution chart, Aquarius Surgical Technologies ranks #71 out of 521 companies in the Medical Devices & Instruments industry, placing it in the top 13.6%.
Is Aquarius Surgical Technologies' Cyclically Adjusted PS Ratio too high?
Aquarius Surgical Technologies' current Cyclically Adjusted PS Ratio of 0.42 is 83% below median its 10-year median of 2.50. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 17.40. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.28. Aquarius Surgical Technologies' value of 0.42 is 81.6% below this industry median. Based on the distribution chart, Aquarius Surgical Technologies ranks #71 out of 521 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Aquarius Surgical Technologies' Cyclically Adjusted PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aquarius Surgical Technologies ranks #71 out of 521 companies for Cyclically Adjusted PS Ratio. This places Aquarius Surgical Technologies in the top 14% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PS Ratio is 2.28. Aquarius Surgical Technologies' value of 0.42 is 81.6% below this benchmark. Historically, Aquarius Surgical Technologies' own Cyclically Adjusted PS Ratio has ranged from 0.17 to 17.40 over the past decade. While the company's 10-year median is 2.50 vs. the industry median of 2.28, Aquarius Surgical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.28, based on 521 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aquarius Surgical Technologies's current Cyclically Adjusted PS Ratio of 0.42 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Aquarius Surgical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aquarius Surgical Technologies's current Cyclically Adjusted PS Ratio is 0.42, which is 83% below median its own 10-year median of 2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquarius Surgical Technologies stock overvalued right now?
Aquarius Surgical Technologies (AQQRF) has a current Cyclically Adjusted PS Ratio of 0.42. The current Cyclically Adjusted PS Ratio is 0.42, which is 83% below median its 10-year median of 2.50 and 81.6% below the Medical Devices & Instruments industry median of 2.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Aquarius Surgical Technologies (AQQRF), the current Cyclically Adjusted PS Ratio is 0.42 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aquarius Surgical Technologies Business Description
Aquarius Surgical Technologies Inc is engaged in the development, sale, distribution, marketing, and exploitation of laser-driven technologies for use in surgical environments. Through its subsidiary, the company operates as an international distributor, service, and support organization providing integrated laser-based solutions across multiple medical disciplines. These disciplines include urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery, many of which are now considered the standard of care for treatment. Geographically, the company generates maximum revenue from the sale of medical devices in the United States, and also has its presence in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQQRF has been successfully added to your 
